about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesNext-generation sequencing of the Chinese hamster ovary microRNA transcriptome: Identification, annotation and profiling of microRNAs as targets for cellular engineeringAdvances in recombinant antibody manufacturingAntibody domain exchange is an immunological solution to carbohydrate cluster recognitionCrystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharidesRecognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicityA human monocytic NF-κB fluorescent reporter cell line for detection of microbial contaminants in biological samplesIdentification of microRNAs specific for high producer CHO cell lines using steady-state cultivation.Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients.Evaluation of the potency of the anti-idiotypic antibody Ab2/3H6 mimicking gp41 as an HIV-1 vaccine in a rabbit prime/boost studyImproved protocol for rapid identification of certain spa types using high resolution melting curve analysis.The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous beta1,4-galactosylated N-glycan profile.Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.Upstream and downstream processing of recombinant IgA.Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12.Transcriptional profiling of phenotypically different Epo-Fc expressing CHO clones by cross-species microarray analysis.Biphasic cultivation strategy to avoid Epo-Fc aggregation and optimize protein expression.Stable overexpression of miR-17 enhances recombinant protein production of CHO cells.Heterologous protein production using euchromatin-containing expression vectors in mammalian cellsBenchmarking of commercially available CHO cell culture media for antibody production.Accurate comparison of antibody expression levels by reproducible transgene targeting in engineered recombination-competent CHO cells.In search of expression bottlenecks in recombinant CHO cell lines--a case study.Novel human renal proximal tubular cell line for the production of complex proteins.Recent advances in recombinant protein production: BAC-based expression vectors, the bigger the better.Topological transformation of liposomes by a membrane-affecting domain of recombinant human erythropoietin.Recombinant IgA production: single step affinity purification using camelid ligands and product characterization.A screening method to assess biological effects of microRNA overexpression in Chinese hamster ovary cells.Growth, productivity and protein glycosylation in a CHO EpoFc producer cell line adapted to glutamine-free growth.Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.Serum-free transfection of CHO cells with chemically defined transfection systems and investigation of their potential for transient and stable transfection.A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits.Antibody humanization by molecular dynamics simulations-in-silico guided selection of critical backmutations.Improvement of the energy metabolism of recombinant CHO cells by cell sorting for reduced mitochondrial membrane potential.Characterisation of recombinant CHO cell lines by investigation of protein productivities and genetic parameters.Process parameter shifting: Part I. Effect of DOT, pH, and temperature on the performance of Epo-Fc expressing CHO cells cultivated in controlled batch bioreactors.Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
P50
Q24561905-B79E1E66-0D1E-4008-AC0F-11CCDEFAD319Q24609224-53716E15-BB68-4A35-89CF-70996690686BQ26764949-8E501D0E-BACB-4401-BC13-24187EE64558Q27641517-08A3E190-3153-4FC6-9928-153E6FD5A94FQ27651506-76DFEB0A-89E1-46A4-B2A2-53C738548A69Q28288481-ACA8B2EA-5080-4A65-B5BE-E4333012AB4FQ28484544-09B563CB-312F-439C-9B33-8861FF8071AEQ33724996-4276B3B8-41BC-4835-B5D9-4A14B20D06CEQ34071633-EA6244A3-6AB0-47E2-A3E1-1E7E0A6FB770Q34240076-238934AE-59EE-4DFE-B1AF-971D77FB784CQ34312108-B21371AE-508F-4C5A-9FAA-81A5A003F1FBQ35174961-B49ACC07-D612-48EC-AAFD-405C0D16083FQ36509423-871CCCBE-F7B3-45BC-A776-5DD36C5945D6Q36898696-C783FDEA-9EF6-4666-B67B-99DAFE3C5A4DQ36954635-DD44F7F6-C794-4319-B669-0BBC245E2224Q37343940-2974CA03-8E30-4F95-A554-A714815BF9AAQ37364364-EE49EBCD-0F8B-41FB-AEB8-9C803A6B0943Q38254478-4B64675C-268B-400B-B03B-0B7C76C98A3DQ38337995-07B50A22-EB06-4980-86EE-18583C2DF906Q38513710-67DFAD65-407B-48A7-87CB-C661AD16792AQ38780320-72A038DF-7C0A-4EA0-876F-371553B01547Q38823900-F96E4CC9-7DD4-4073-93EE-FC9BABD33B7EQ38874558-5FDBF946-1E45-4BD4-8565-3C05FA5C9E53Q38890492-FF9EE87F-58C8-432D-88BC-C350BECB573AQ38962658-0AC8C469-9A2E-42F2-8D05-DE9CA7703B78Q39021972-5CD3CFD4-9196-48A2-A8BB-DB720D06ACF7Q39022456-4CDBF3FE-3B8A-4B19-9E3E-775222D3F032Q39150976-5EE7A759-94EE-42FD-8703-5C06EE4CD8CDQ39343029-9D979584-80C1-448E-A105-04ABBD8036B9Q39351535-7F484A26-D7FC-4435-9C37-1E274ADDB76BQ39381640-7F8DD1F3-82A8-4311-B2DF-191A9D77125DQ39426488-B4F05C19-EAF1-4436-93D6-DB1D750C11CCQ39637236-B76CF585-D657-48E9-B1AB-F0894B695D3FQ39798607-9B9BCF5E-2EA3-4093-BCEA-ABEB9210039EQ40023382-737AA500-25B2-49DE-9882-0BF1749E25C6Q40125548-CDEBE2DA-5977-464F-AC85-0791A10FCA6AQ40156448-AEACB288-ED8B-41AC-B5A8-AE8CCA5516EFQ40166354-4F45EFC5-9C73-4997-92F6-6F2CAC08713CQ40273503-F11806DC-7404-4363-A459-93998BE289D7Q40410850-E204A180-9726-4B64-82FB-EA7F12E0B32B
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Renate Kunert
@ast
Renate Kunert
@en
Renate Kunert
@es
Renate Kunert
@nl
Renate Kunert
@sl
type
label
Renate Kunert
@ast
Renate Kunert
@en
Renate Kunert
@es
Renate Kunert
@nl
Renate Kunert
@sl
prefLabel
Renate Kunert
@ast
Renate Kunert
@en
Renate Kunert
@es
Renate Kunert
@nl
Renate Kunert
@sl
P1053
B-9185-2018
P106
P1153
6603682350
P21
P31
P3829
P496
0000-0002-3397-3621